[go: up one dir, main page]

UA88294C2 - Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation - Google Patents

Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Info

Publication number
UA88294C2
UA88294C2 UAA200610138A UAA200610138A UA88294C2 UA 88294 C2 UA88294 C2 UA 88294C2 UA A200610138 A UAA200610138 A UA A200610138A UA A200610138 A UAA200610138 A UA A200610138A UA 88294 C2 UA88294 C2 UA 88294C2
Authority
UA
Ukraine
Prior art keywords
cancer
antibodies
methods
cancer cell
cell proliferation
Prior art date
Application number
UAA200610138A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Ванита Рамакришнан
Винай Бхаскар
Суй Хо
Ричард Муррей
Дебби Ло
Original Assignee
Фейсит Биотек Корпорейшен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фейсит Биотек Корпорейшен filed Critical Фейсит Биотек Корпорейшен
Publication of UA88294C2 publication Critical patent/UA88294C2/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods for direct killing of cancer cells using anti- α5β1 antibodies. Generally, the method comprises contacting a cancer cell that expresses α5β1 on its surface with an anti-α5β1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-α5β1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.
UAA200610138A 2004-03-24 2005-03-24 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation UA88294C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55642104P 2004-03-24 2004-03-24

Publications (1)

Publication Number Publication Date
UA88294C2 true UA88294C2 (en) 2009-10-12

Family

ID=37879292

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200610138A UA88294C2 (en) 2004-03-24 2005-03-24 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Country Status (3)

Country Link
CN (1) CN1933851B (en)
UA (1) UA88294C2 (en)
ZA (1) ZA200607849B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2596361A1 (en) * 2010-07-19 2013-05-29 F.Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
US8946159B2 (en) * 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
CA3121288A1 (en) * 2018-11-29 2020-06-04 Harbour Biomed Therapeutics Limited Anti-pd-l1 antibody preparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis

Also Published As

Publication number Publication date
ZA200607849B (en) 2007-12-27
CN1933851B (en) 2011-09-14
CN1933851A (en) 2007-03-21

Similar Documents

Publication Publication Date Title
IL178042A0 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
EA200601433A1 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF TUMORS AND METASTASIS
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
EA200801853A1 (en) EFFECTIVE PEPTIDES IN THE TREATMENT OF TUMORS AND OTHER DISEASES THAT REQUIRE REMOVAL OR DESTRUCTION OF CELLS
MX2009006779A (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors.
DE602005027617D1 (en) RADIO THERAPY TREATMENT MONITORING USING ULTRASOUND
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
NZ626867A (en) Compositions and methods for the treatment of infections and tumors
WO2004064727A3 (en) Method of cancer treatment using hdac inhibitors
WO2004000094A3 (en) Predictive markers in cancer therapy
EA201001695A1 (en) APPLICATION OF EPOTHILON D FOR THE TREATMENT OF DISEASES ASSOCIATED WITH TAU-PROTEIN
DE60027768D1 (en) TREATMENT OF METASTATIC DISEASE
WO2020107002A3 (en) Methods for expansion of natural killer (nk) cell subset and related compositions and methods
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
ATE526037T1 (en) METHOD FOR KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGENS EXPOSED ON APOPTOTIC TUMOR CELLS
EP1708752A4 (en) ANTICANCER THERAPEUTIC AGENT CONSISTING OF ANTIBODY RELATED TO A POLYMER
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
WO2008083326A3 (en) Targeting of ews-fli1 as anti-tumor therapy
TNSN06059A1 (en) Use of polypeptides of the cupredoxin family in cancer therapy
MXPA05008794A (en) Glycorpotein antigen sima135 expressed in metastatic human tumor cells.
EA200970884A1 (en) METHODS OF TREATING CANCER BY INTRODUCING HUMAN INTERLEUKIN IL-18 COMBINATIONS
WO2004031231A3 (en) Genes and polypeptides relating to prostate cancers
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
DE60038624D1 (en) METHODS OF TREATING SOLID TUMORS AND METASTASES WITH GENE THERAPY
IS5570A (en) Treatment of giant lupus erythematosus with the adenocytes